SignalPoint Asset Management LLC increased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 13.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,581 shares of the medical research company’s stock after buying an additional 790 shares during the quarter. SignalPoint Asset Management LLC’s holdings in Exact Sciences were worth $460,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in EXAS. CarsonAllaria Wealth Management Ltd. bought a new position in Exact Sciences during the 4th quarter worth about $37,000. FSB Premier Wealth Management Inc. bought a new position in shares of Exact Sciences in the 4th quarter valued at about $36,000. Masso Torrence Wealth Management Inc. bought a new position in shares of Exact Sciences in the 4th quarter valued at about $37,000. HM Payson & Co. grew its holdings in shares of Exact Sciences by 118.6% in the 4th quarter. HM Payson & Co. now owns 481 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 261 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in shares of Exact Sciences by 1,017.8% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 503 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 458 shares in the last quarter. Institutional investors and hedge funds own 94.45% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on EXAS shares. Craig Hallum reduced their price target on Exact Sciences from $81.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Citigroup dropped their price target on shares of Exact Sciences from $65.00 to $50.00 and set a “neutral” rating for the company in a research report on Wednesday. BTIG Research dropped their price target on shares of Exact Sciences from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday. Raymond James dropped their price target on shares of Exact Sciences from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, StockNews.com upgraded shares of Exact Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.09.
Insider Activity at Exact Sciences
Exact Sciences Stock Down 4.7 %
EXAS stock traded down $2.32 during trading on Friday, reaching $47.05. The stock had a trading volume of 2,885,678 shares, compared to its average volume of 1,783,264. Exact Sciences Co. has a one year low of $35.34 and a one year high of $108.99. The company has a current ratio of 2.48, a quick ratio of 2.29 and a debt-to-equity ratio of 0.70. The company’s 50 day moving average is $44.58 and its two-hundred day moving average is $59.00.
Exact Sciences Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.
- Get a free copy of the StockNews.com research report on Exact Sciences (EXAS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.